The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Open accessAbstract
Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis. Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented. This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essential. Treatment including application of steroids is critical for patient safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cardiac biopsies from patients with ICI myocarditis revealed myocardial infiltration primarily by T cells”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [118]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“one of the best examples of drug-induced lymphocytic myocarditis is ICI myocarditis, which may occur following ICI treatment in patients with cancer.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [118]
The cited source says what the claim attributes to it.
In the citing paper
“suggesting a potential role of T cells in driving the pathogenesis of this condition.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citationTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citationAutoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Research works printed but not linked: 1
- Larkin J, D’Angelo S, Sosman JA, Lebbe C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab (NIVO) monotherapy in the treatment of advanced mucosal melanoma. Pigment Cell Melanoma Res. 2016;28:789.
Cited by
Sorted by citations
Items 501–510 of 510
CARDIOVASCULAR EFFECTS OF ONCOLOGY THERAPIES
Giza, A., Marzec, U., Cyrkler, A., Cieślak, N., Dąbek, K., Rajca, E., Paulina, G. I. Z. A., Wymoczył, K., Czyżak, K., & Chodkowska, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5087
Troponin/Lymphocyte Ratio: Anticipating Immunotherapy-Induced Myocarditis
Miranda, I., & Augusto, J. B. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250867i
Yu, D., Liu, H., Zhang, J., Li, X. T., Yu, Y., & Lyu, H. (2026) · Journal of Cardio-oncology · doi:10.1097/co9.0000000000000021
Milinković, I., Simeunović, D. S., Veljić, I., Gatarić, N., Peric, V., Marija, B., Obradović, V., Zaharijev, S., Gagić-Zaharijev, A., Simeunović, F., et al. (2026) · Medicinska istrazivanja · doi:10.5937/medi0-64448
Immunotherapy in Asia: current insights and prospects in Southeast Asia and Malaysia
Bustamam, R. S., & Phoon, Y. P. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1847284
Serban, D.-V., Mateescu, D.-M., Crainic, D., Ivanovic, N., Fericean, R. M., Bojin, F. M., Toma, A.-O., Jurj, E.-D., Clej, E. E., & Păunescu, V. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187022
Immunotherapy-Related Cardiac Arrythmias: Incidence, Pathobiology, Risk Factors and Management
Agarwal, M. A., Mohammad, F., Agdamag, A. C., Guha, A., Yang, E. H., Shafei, F., Ismail, G., Khan, H., Zaki, A. A., Grobmeyer, S., et al. (2026) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-026-00792-1
Shaikh, F., Ferreira, M. H. L., Ananda, R., Raja, S., de Aguiar, D. R., Gul, A., Román, A. C. B., Khatiwada, K., Solanki, R., Mattoso, S. O., et al. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02702-3
Cheikh, J. E., Wehbeh, B. E. D., Tarhini, A., Mansour, R., Sayde, G., Charbel, N., Kautaich, K., Hasan, I., & Refaat, M. M. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.019
Zhao, T., Chen, R., Ma, Y., Li, G., Gu, X., Chen, Y., & Sun, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.2003924
Metadata
- Authors
- Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J.
- Affiliations
- Universitätsklinikum Erlangen (DE)
- Dana-Farber Cancer Institute (US)
- University of Chicago (US)
- The University of Texas MD Anderson Cancer Center (US)
- Paracelsus Medizinische Privatuniversität (DE)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Corresponding author
- Heinzerling, Lucie
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2016-08-16
- Volume
- 4
- Issue
- 1
- Pages
- 50-50
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC4986340
- OpenAlex
- W2478478625
- Cited by
- 511
- References
- 37
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 34 · 2023: 43 · 2022: 50 · 2021: 77 · 2020: 78 · 2019: 64 · 2018: 61 · 2017: 50 · 2016: 2
- FWCI
- 31.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion, cc-by)
- Funders
- Melanoma Research Alliance
- Celldex Therapeutics
- National Institutes of Health
- Genentech
- National Cancer Institute (K12CA139160)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
- Keywords
- immune-related cardiotoxicity, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint inhibitors, ipilimumab, nivolumab, pembrolizumab, myocarditis, pericarditis, heart failure, cardiomyopathy, myocardial fibrosis, atrioventricular block, corticosteroid therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
